AR016294A1 - Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion - Google Patents

Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion

Info

Publication number
AR016294A1
AR016294A1 ARP980103180A ARP980103180A AR016294A1 AR 016294 A1 AR016294 A1 AR 016294A1 AR P980103180 A ARP980103180 A AR P980103180A AR P980103180 A ARP980103180 A AR P980103180A AR 016294 A1 AR016294 A1 AR 016294A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
heteroaryl
cr10r20
ring
Prior art date
Application number
ARP980103180A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR016294A1 publication Critical patent/AR016294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Un compuesto de imidazol sustituido porque está representado por la formula (I) en la que: R1 es un anillo de 4-piridilo, pirimidinilo, 4-piridazinilo,1,2,4-triazin-5-ilo, quinolilo, isoquinolilo o quinazolin-4-ilo, cuyo anillo está sustituido con Y-Ra y opcionalmente con un sustituyente independienteadicional, seleccionado entre alquilo C1-4, halogeno, hidroxilo, alcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, CH2OR12, amino, amino mono- y di-sustituido con alquilo C1-6, un anillo de N-heterociclilo, cuyo anillo tiene de 5 a 7 miembros y contiene opcionalmente un heteroátomo adicional seleccionadoentre oxígeno, azufre o NR15, N(R10)C(O)Rb o NHRa; Y es oxígeno o azufre; R4 es fenilo, naft-1-ilo o naft-2-ilo, o un heteroarilo, que opcionalmente estásustituido con uno o dos sustituyentes, cada uno de los cuales se selecciona independientemente, y que, para un sustituyente de 4-fenilo, 4-naft-1-ilo,5-naft-2-ilo o 6-naft-2-ilo, es halogeno, ciano, nitro, C(Z)NR7R17, C(Z)OR16, (CR10R20)vCOR12, SR5, SOR5, OR12, alquilo C1-4 sustituido con halo, alquiloC1-4, ZC(Z)R12, NR10C(Z)R16 o (CR10R20)vNR10R20 y que, para otras posiciones de sustitucion, es halogeno, ciano, C(Z)NR13R14, C(Z)OR3, (CR10R20)mCOR3, S(O)mR3, OR3, alquilo C1-4 sustituido con halo, alquilo C1-4, (CR10R20)mNR10C(Z)R3, NR10S(O)mR8, NR10S(O)mNR7R17, ZC(Z)R3 o (CR10R20)mNR13R14; Z es oxígenoo azufre; n es un numero entero que tiene un valor de 1 a 10; m es 0 o el numero entero 1 o 2; m es un numero entero que tiene un valor de 1 o 2; m es 0, oun numero entero que tiene un valor de 1 a 5; v es 0, o un numero entero que tiene un valor de 1 o 2; R2 es -C(H)(A)(R22); A es un anillo de arilo,heterociclico o heteroarilo opcionalmente sustituido, o A es un alquilo C1-10 sustituido; R22 es un alquilo C1-10 opcionalmente sustituido; Ra es arilo,aril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, pudiendo cada uno de estos restos estar opcionalmentesustituido; Rb es hidrogeno, alquilo C1-6, cicloalquilo C3-7, arilo, arilalquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo o
ARP980103180A 1997-07-02 1998-06-30 Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion AR016294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5159297P 1997-07-02 1997-07-02

Publications (1)

Publication Number Publication Date
AR016294A1 true AR016294A1 (es) 2001-07-04

Family

ID=21972242

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103180A AR016294A1 (es) 1997-07-02 1998-06-30 Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion

Country Status (22)

Country Link
EP (2) EP1014976B1 (es)
JP (2) JP2002507994A (es)
KR (1) KR20010014420A (es)
CN (1) CN1134420C (es)
AR (1) AR016294A1 (es)
AT (1) ATE290001T1 (es)
AU (1) AU8381298A (es)
BR (1) BR9810342A (es)
CA (2) CA2294524A1 (es)
CO (1) CO4950624A1 (es)
CZ (1) CZ9904750A3 (es)
DE (2) DE69829192T2 (es)
ES (2) ES2207847T3 (es)
HU (1) HUP0002050A3 (es)
IL (3) IL133035A0 (es)
NO (1) NO996572D0 (es)
NZ (1) NZ500922A (es)
PL (1) PL337738A1 (es)
TR (1) TR200000014T2 (es)
TW (1) TW536539B (es)
WO (2) WO1999001130A1 (es)
ZA (1) ZA985763B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
CA2306077A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2004004725A2 (en) * 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
WO2005058834A2 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
MXPA06012512A (es) * 2004-04-28 2007-02-08 Tanabe Seiyaku Co Compuesto heterociclico.
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2013337297A1 (en) * 2012-11-05 2015-05-21 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutical applications
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US20230271953A1 (en) * 2019-11-29 2023-08-31 Facio Intellectual Property B.V. Novel compounds for treatment of diseases related to DUX4 expression
WO2021105474A1 (en) * 2019-11-29 2021-06-03 Facio Intellectual Property B.V. New compounds for treatment of diseases related to dux4 expression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ188244A (en) * 1977-09-13 1981-04-24 Ici Australia Ltd 2-substituted pyrimidines compositions growth regulating processes
CA1175431A (en) * 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
JPH082883B2 (ja) * 1986-06-06 1996-01-17 クミアイ化学工業株式会社 ２−フエノキシピリミジン誘導体および除草剤
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
KR19980701374A (ko) * 1995-01-12 1998-05-15 스티븐 베네티아너 신규 화합물(Novel Compounds)
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
KR19990077164A (ko) * 1996-01-11 1999-10-25 스티븐 베네티아너 신규 치환된 이미다졸 화합물
EP1005343A4 (en) * 1996-03-08 2000-06-07 Smithkline Beecham Corp USE OF CSAIDS AS ANGIOGENESIS INHIBITORS
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM

Also Published As

Publication number Publication date
ATE290001T1 (de) 2005-03-15
DE69829192D1 (de) 2005-04-07
JP2002507992A (ja) 2002-03-12
NZ500922A (en) 2001-12-21
IL133035A0 (en) 2001-03-19
DE69829192T2 (de) 2006-02-16
CO4950624A1 (es) 2000-09-01
ES2207847T3 (es) 2004-06-01
EP1014976A4 (en) 2001-08-29
CN1261277A (zh) 2000-07-26
CA2294524A1 (en) 1999-01-14
BR9810342A (pt) 2000-09-05
AU737637B2 (en) 2001-08-23
EP0996446A4 (en) 2001-08-29
WO1999001131A1 (en) 1999-01-14
ZA985763B (en) 1999-01-19
IL190215A0 (en) 2008-11-03
EP0996446B1 (en) 2003-09-17
CN1134420C (zh) 2004-01-14
TW536539B (en) 2003-06-11
KR20010014420A (ko) 2001-02-26
DE69818266T2 (de) 2004-07-15
AU8381298A (en) 1999-01-25
WO1999001130A1 (en) 1999-01-14
PL337738A1 (en) 2000-08-28
TR200000014T2 (tr) 2000-11-21
IL190216A0 (en) 2008-11-03
EP1014976B1 (en) 2005-03-02
DE69818266D1 (de) 2003-10-23
HUP0002050A3 (en) 2002-04-29
CZ9904750A3 (cs) 2001-12-12
ES2237843T3 (es) 2005-08-01
EP1014976A1 (en) 2000-07-05
EP0996446A1 (en) 2000-05-03
NO996572L (no) 1999-12-30
JP2002507994A (ja) 2002-03-12
CA2294522A1 (en) 1999-01-14
NO996572D0 (no) 1999-12-30
HUP0002050A2 (hu) 2001-04-28
AU8381598A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
AR016294A1 (es) Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
AR013172A1 (es) Compuestos de imidazol sustituido, composicion farmaceutica que lo contiene, el uso del mismo en la manufactura de un medicamento y procedimientopara su preparacion
AR006307A1 (es) Compuestos de imidazol 5-piridinil o 5-pirimidinil sustituidos, composicion farmaceutica, uso de dichos compuestos para prepararmedicamentos y procedimiento para preparar dichos compuestos.
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
TR200003256T2 (tr) P-38 mapkinaz engelleyicileri olan pirazol türevleri
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR023681A1 (es) Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.
CO5370680A1 (es) Nuevos compuestos
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
TR199801942T2 (xx) Piperazin ve piperidin bile�ikleri.
DK0687251T3 (da) 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister
AR028531A1 (es) Compuestos organicos
DE60100506D1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
KR960014112A (ko) 자외선 흡수제, 이의 제조방법 및 용도
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
ATE9336T1 (de) 3,1-benzoxazin-2-one, ihre herstellung und verwendung.
ATE26266T1 (de) Pyridazinone, ihre herstellung und verwendung, pyridazinone enthaltende arzneimittel.
BR0113452A (pt) Derivados de 4-, 5-, 6- e 7- indol úteis para o tratamento de distúrbios do snc, o composto; sua composição farmacêutica e uso do mesmo
NO910167D0 (no) Haarfargemiddel.
CY1106317T1 (el) Παραγωγα 1-ν-φαινυλαμινο-1η-ιμιδαζολης, ως αναστολεις αρωματασης
PE20040205A1 (es) Derivados de azepano como inhibidores de la quinasa akt1
ATE112303T1 (de) Beschichtungszusammensetzungen.
DE69633289D1 (de) 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten
ES8500742A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal